

**FACSIMILE TRANSMISSION**

Transmission problems: (858) 720-2720

**October 31, 2001****FAX RECEIVED**

NOV 01 2001

**GROUP 1600****Brobeck**

ATTORNEYS AT LAW

Brobeck, Phleger &amp; Harrison LLP

12750 High Bluff

Suite 300

San Diego, California 92130-2081

PHONE 858.720.2500

FAX 858.720.3700

www.brobeck.com

PAGES TO FOLLOW COVER	//	USER ID	<u>100495</u>	CMID NUMBER	<u>030639.0034.CPA2</u>
-----------------------	----	---------	---------------	-------------	-------------------------

**TO**

RECIPIENT	COMPANY	TELEPHONE	FAX
Examiner Patrick Nolan	PTO	(703) 305-1987	(703) 305-7401

**FROM**

SENDER	EMAIL	TELEPHONE	FAX
Bradford J. Duft	bduft@brobeck.com	(858) 720-2720	(858) 720-3700

**MESSAGE**

[start message here]

**OFFICIAL****PRIVILEGED AND CONFIDENTIAL**

All information transmitted hereby is intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and mail the original message to us at the above address.

C

Patent  
030639.0034.CPA2IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re the Application of:  
**Dupre**

Serial No.: 09/280,020

Filed: March 29, 1999

For: **TREATMENT OF DIABETES**

Group Art Unit: 1644

Examiner: Patrick Nolan, Ph.D.

19  
C  
11/10/01RESPONSE**OFFICIAL**Commissioner for Patents  
Washington, D.C. 20231

Dear Commissioner:

In response to the Office Action mailed July 31, 2001, in the above-referenced case, Applicant respectfully requests entry of the following amendments and consideration of the following remarks.

In the Abstract

Please replace the abstract as follows. The abstract is also included on a separate sheet enclosed herewith.

"A method of treating insulin-requiring diabetes in a mammal comprising administering to the mammal an effective amount of a glucagon-like peptide 1-related peptide."

In the Claims

Please amend claims 15, 17-20, 22-25, 27-30, and 32-34 as follows. A marked version showing changes made is appended hereto.

C